Literature DB >> 8224164

The gag precursor contains a specific HIV-1 protease cleavage site between the NC (P7) and P1 proteins.

E M Wondrak1, J M Louis, H de Rocquigny, J C Chermann, B P Roques.   

Abstract

The predicted protease cleavage site (p7/p1; [J. Virol. 66 (1992) 1856-1865]) within the nucleocapsid precursor protein (p15) of human immunodeficiency virus, type 1, was confirmed using an in vitro assay employing recombinant HIV-1 protease and a chemically synthesized 72 amino acid polypeptide containing the p7 and p1 protein domains of the native gag polyprotein. The cleavage occurred between amino acid 55 (N) and amino acid 56 (F) of the polypeptide, as determined by N-terminal sequencing. The hydrolysis was optimal at pH 6.0 and at high salt concentration. The kinetic parameters Km, kcat and kcat/Km were 99 microM (+/- 8), 0.152 s-1 (+/- 0.002) and 1.56 mM-1.s-1 (+/- 0.11), respectively. Reconstituted as well as denatured polypeptides were cleaved at approximately the same rate, demonstrating that the conformation of the p7 protein, as a result of the Zn(2+)-binding, had no significant effect on the rate of hydrolysis of the p7/p1 cleavage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8224164     DOI: 10.1016/0014-5793(93)80367-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Authors:  H C Côté; Z L Brumme; P R Harrigan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Roles of the human immunodeficiency virus type 1 nucleocapsid protein in annealing and initiation versus elongation in reverse transcription of viral negative-strand strong-stop DNA.

Authors:  L Rong; C Liang; M Hsu; L Kleiman; P Petitjean; H de Rocquigny; B P Roques; M A Wainberg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

5.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.

Authors:  L Doyon; G Croteau; D Thibeault; F Poulin; L Pilote; D Lamarre
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Identification of folding preferences of cleavage junctions of HIV-1 precursor proteins for regulation of cleavability.

Authors:  Hirotaka Ode; Masaru Yokoyama; Tadahito Kanda; Hironori Sato
Journal:  J Mol Model       Date:  2010-05-18       Impact factor: 1.810

7.  Effect of mutation on the stabilization energy of HIV-1 zinc fingers: a hybrid local self-consistent field/molecular mechanics investigation.

Authors:  Nedjoua Drici; Mohamed Abdelghani Krallafa
Journal:  J Biol Inorg Chem       Date:  2016-11-15       Impact factor: 3.358

8.  Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing.

Authors:  G Zybarth; C Carter
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Cleavage of p15 protein in vitro by human immunodeficiency virus type 1 protease is RNA dependent.

Authors:  N Sheng; S Erickson-Viitanen
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

10.  In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.

Authors:  A Carrillo; K D Stewart; H L Sham; D W Norbeck; W E Kohlbrenner; J M Leonard; D J Kempf; A Molla
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.